Showing 15 posts of 275 posts found.

Beyond Batten Disease Foundation partners with Actelion on development of combination treatment

March 4, 2021
Actelion, Batten disease, Janssen

Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of …

FDA approves Johnson & Johnson’s COVID-19 vaccine for emergency use

March 1, 2021
Sales and Marketing COVID-19, Janssen, Johnson & Johnson, vaccines

The FDA has issued emergency use authorisation for Johnson & Johnson’s one-shot COVID-19 vaccine, approving the jab for use in …


Janssen announces positive Phase III results for prostate cancer drug apalutamide

February 10, 2021
Research and Development Cancer, Janssen

Final results from Janssen’s Phase III TITAN study have shown its cancer drug apalutamide improved overall survival (OS) in patients …


Janssen’s esketamine nasal spray gets Europe approval for new indication

February 9, 2021
Manufacturing and Production Europe, Janssen

The European Commission (EC) has authorised the expanded use of Janssen’s Spravato (esketamine nasal spray), co-administered with oral antidepressant therapy in …


FDA approves Janssen’s AL amyloidosis drug

January 18, 2021
Sales and Marketing FDA, Janssen

The FDA has approved Janssen’s DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone …


EMA receives filing for Janssen’s twice-yearly schizophrenia jab

December 7, 2020
Sales and Marketing EMA, Janssen, schizophrenia

The European Medicines Agency (EMA) has received Janssen’s Marketing Authorisation Extension for paliperidone palmitate six-monthly (PP6M), an injectable therapy administered …


Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia

December 7, 2020
Research and Development, Sales and Marketing Janssen, chronic lymphocytic leukaemia, imbruvica

Janssen has revealed multiple pooled data analyses for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in the first-line treatment …


Janssen scoops up rights to Hemera’s gene therapy for retinal geographic atrophy

December 3, 2020
Sales and Marketing Hemera Biosciences, Janssen, Retina, geographic atrophy

Janssen is set to acquire the rights to Hemera Biosciences’ intravitreal gene therapy injection HMR59, the company has announced, to …


European approval for Janssen’s Tremfya in active psoriatic arthritis, either alone or in combo

December 2, 2020
Research and Development, Sales and Marketing Europe, Janssen, Tremfya

The European Commission has authorised Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) in the treatment of active psoriatic arthritis (PsA), either …


Renewed BARDA backing boosts J&J’s COVID-19 vaccine funding by $1bn

November 17, 2020
Manufacturing and Production, Research and Development BARDA, COVID-19, J&J, JJ, Janssen, Vaccine

Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop …

J&J launches second global COVID-19 vaccine trial, evaluating two-dose regimen

November 16, 2020
Research and Development, Sales and Marketing COVID-19, J&J, JJ, Janssen, Vaccine

Johnson & Johnson has kicked off a second global Phase 3 trial to assess the safety and efficacy of its …


CHMP recommendation for Janssen’s Tremfya in active psoriatic arthritis

October 19, 2020
Sales and Marketing CHMP, EMA, Janssen, Tremfya

Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) has scored a recommendation from the EMA’s Committee for Medicinal Products for Human Use …


European Commission agrees deal with Janssen for 200 million doses of its COVID-19 vaccine

October 9, 2020
Medical Communications AZ, AstraZeneca, Janssen

The European Commission has approved an agreement with Johnson & Johnson for the supply of 200 million doses of Janssen’s …


Janssen’s Imbruvica secures label expansion in Europe in chronic lymphocytic leukaemia

September 7, 2020
Sales and Marketing Europe, Janssen, imbruvica, pharma

The European Commission (EC) has moved to expand the existing approval of Janssen’s Imbruvica (ibrutinib) in chronic lymphocytic leukaemia (CLL) …

NICE knocks back Janssen’s Spravato nasal spray for the second time in treatment-resistant depression

September 3, 2020
Sales and Marketing Janssen, Spravato, depression, pharma

NICE has opted to reject Janssen’s nasal spray Spravato (esketamine) for routine use on the NHS for treatment-resistant major depressive …

Latest content